Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently announced that it has received alignment from the U.S. Food and Drug Administration (FDA) on the design of a …
Ocugen Gains FDA Alignment for Phase 3 Trial of Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a Pennsylvania-based biopharmaceutical company, has scored a significant regulatory milestone this week with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine …
Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently made a significant stride in its quest for innovative vision restoration solutions. The company announced that the first patient …
Ocugen’s Pioneering Gene Therapy OCU410 Takes Major Step Forward in Clinical Trials Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in the discovery, development, and commercialization of gene and cell therapies, biologics, and vaccines, has announced that its Chairman, …
Ocugen CEO to Address Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced the commencement of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate being developed to …
Ocugen Initiates Phase 1/2 GARDian Clinical Trial for Stargardt Disease Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a frontrunner in the world of biopharmaceuticals, recently disclosed its Q3 2023 financial results and a business update that holds promising news for …
Ocugen’s Promising Advancements: Q3 2023 Financial Results and Progress in Ophthalmic Gene Therapies, Regenerative Cell Therapies, and Vaccines Portfolio Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at the prestigious 4th Annual Dry AMD Therapeutic …
Ocugen’s Chief Scientific Officer to Speak at the 4th Annual Dry AMD Therapeutic Development Summit Read More MALVERN, PA — Ocugen, Inc. ((NASDAQ: OCGN) announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2023 financial results and provide a …
Ocugen to Host Conference Call to Discuss Business Updates and Third Quarter 2023 Financial Results Read More